LEADER 02496oam 2200637 450 001 9910715923403321 005 20210421102313.0 035 $a(CKB)5470000002516864 035 $a(OCoLC)681282566$z(OCoLC)631201054$z(OCoLC)667877813$z(OCoLC)985368881$z(OCoLC)1153330270 035 $a(OCoLC)995470000002516864 035 $a(EXLCZ)995470000002516864 100 $a20101113d1993 ua 0 101 0 $aeng 135 $aurbn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBrine contamination of ground water and streams in the Baxterville Oil Field area, Lamar and Marion counties, Mississippi /$fby Stephen J. Kalkhoff 210 1$aJackson, Mississippi :$cU.S. Geological Survey,$d1993. 215 $a1 online resource (v, 37 pages) $cillustrations, maps 225 1 $aWater-resources investigations report ;$v93-4147 300 $a"Prepared in cooperation with the Mississippi Department of Environmental Quality, Office of Pollution Control." 320 $aIncludes bibliographical references (pages 27-28). 606 $aGroundwater$xSodium content$zMississippi$zLamar County 606 $aGroundwater$xSodium content$zMississippi$zMarion County 606 $aGroundwater$xPollution$zMississippi$zLamar County 606 $aGroundwater$xPollution$zMississippi$zMarion County 606 $aOil fields$zMississippi$zLamar County 606 $aOil fields$zMississippi$zMarion County 606 $aGroundwater$xPollution$2fast 606 $aGroundwater$xSodium content$2fast 607 $aMississippi$zLamar County$2fast 607 $aMississippi$zMarion County$2fast 615 0$aGroundwater$xSodium content 615 0$aGroundwater$xSodium content 615 0$aGroundwater$xPollution 615 0$aGroundwater$xPollution 615 0$aOil fields 615 0$aOil fields 615 7$aGroundwater$xPollution. 615 7$aGroundwater$xSodium content. 700 $aKalkhoff$b Stephen J.$01396393 712 02$aGeological Survey (U.S.), 712 02$aMississippi.$bOffice of Pollution Control. 801 0$bOCLCE 801 1$bOCLCE 801 2$bOCLCQ 801 2$bOCLCF 801 2$bOCLCO 801 2$bOCLCQ 801 2$bCOP 801 2$bGPO 906 $aBOOK 912 $a9910715923403321 996 $aBrine contamination of ground water and streams in the Baxterville Oil Field area, Lamar and Marion counties, Mississippi$93515856 997 $aUNINA LEADER 02933nam 2200337z- 450 001 996320739703316 005 20231214133444.0 035 $a(CKB)5340000000058072 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/71145 035 $a(EXLCZ)995340000000058072 100 $a20202107d2018 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPerspectives on treating hypertension in old age$eThe burden of polypharmacy, risks of treatment and GPs? treatment probability 210 $aRotterdam$cOPTIMA$d2018 311 $a94-6361-126-6 330 $aWith increasing age, blood pressure rises as a consequence of arterial stiffness and it has been debated whether or not to it is beneficial to treat hypertension in old age especially in >75-year-olds when they have multimorbidity, polypharmacy or frailty. Large hypertension trials showed that lowering SBP in >60-year-olds is beneficial and lowers the risk for myocardial infarction, stroke and all-cause mortality, even in >80-year-olds. However, these trials lack generalizability and typically excluded multimorbid patients that are frail. At the same time, observational studies rose concerns about lowering SBP too much since there are several cohort studies showing a reverse association of low SBP and increased mortality and accelerated cognitive decline especially in >75-year-olds. However, current hypertension guidelines advise physicians to lower SBP to values of even <130mmHg in all patients from the age of 60 years, which fuelled the discussions about the benefits and harms of lowering SBP too much in >75-year-olds under antihypertensive treatment especially when they are frail defined as having low hand grip strength or complex health problems in multiple domains of daily living. The general aim of this thesis is to increase the scientific knowledge about the effects of treating hypertension in >75-year-olds with frailty. This thesis has three aims: 1) to measure the prevalence of polypharmacy in older patients; 2) to test for an association between low SBP and mortality, cognitive function, daily functioning, and QoL in older patients under antihypertensive treatment; and 3) to understand the role that frailty plays in GP decisions about treating hypertension in old age across countries and see if those differences can be explained by country-specific cardiovascular disease burden and life expectancy. 517 $aPerspectives on treating hypertension in old age 606 $aCardiovascular medicine$2bicssc 610 $aHypertension 610 $aOld Age 610 $aFraitly 615 7$aCardiovascular medicine 700 $aStreit$b Sven$4auth$0988614 906 $aBOOK 912 $a996320739703316 996 $aPerspectives on treating hypertension in old age$92992010 997 $aUNISA